Astellas Pharma vs. Apsen: Modified Release Drug Patent Invalidated
Was möchten Sie als Nächstes tun?
Wählen Sie Ihren Weg entsprechend Ihren aktuellen Bedürfnissen:
📋 Fallzusammenfassung
| Fallbezeichnung | Astellas Pharma, Inc. v. Apsen Farmacêutica S/A |
| Fallnummer | 2332814-55.2023.8.26.0000/50001 |
| Gericht | Court of Justice of São Paulo (Tribunal de Justiça do Estado de São Paulo — TJSP) |
| Dauer | Closed: April 2, 2024 |
| Ergebnis | Patent für ungültig erklärt |
| Streitige Patente | |
| Beschuldigte Produkte | Modified release oral pharmaceutical composition and its manufacturing process |
Fallübersicht
Die Parteien
⚖️ Kläger
Tokyo-headquartered global pharmaceutical company with a substantial portfolio of branded pharmaceutical products, including formulation-specific patents.
🛡️ Beklagter
Brazilian pharmaceutical manufacturer with a portfolio spanning branded generics and specialty pharmaceuticals, a domestic competitor.
Das streitige Patent
This landmark case involved Brazilian patent BRPI0919466B1 covering a modified release oral pharmaceutical composition and its manufacturing process. Modified release formulations represent a significant class of pharmaceutical intellectual property, governing how active pharmaceutical ingredients are delivered over time within the body. These patents often extend effective market exclusivity beyond the primary compound patent and are frequently targeted in invalidity proceedings.
- • BRPI0919466B1 — Modified release oral pharmaceutical composition and its manufacturing process
Entwickeln Sie ein ähnliches pharmazeutisches Produkt?
Check if your modified release drug formulation might infringe existing or related patents before launch.
Das Urteil und die rechtliche Analyse
Ergebnis
The Court of Justice of São Paulo closed case No. 2332814-55.2023.8.26.0000/50001 with the **invalidation of patent BRPI0919466B1**. The ruling, finalized on April 2, 2024, came after Apsen Farmacêutica S/A pursued an invalidity and cancellation action, a defense strategy increasingly deployed by Brazilian generic and specialty pharmaceutical manufacturers.
Wichtige rechtliche Fragen
The operative cause of action was an **invalidity/cancellation action** (ação de nulidade de patente) under Brazilian Industrial Property Law (Law No. 9.279/1996, Article 56). The court’s final ruling addressed appellate objections under **Article 1.025 of Brazil’s CPC**, the pre-questioning provision, affirming the invalidity outcome and declining to reopen substantive questions already resolved.
This decision highlights the vulnerability of formulation patents — even those covering commercially significant modified release technologies — to validity challenges in Brazilian courts, reinforcing the pattern of tribunals applying rigorous patentability standards to pharmaceutical formulation claims.
Freedom-to-Operate-Analyse (FTO)
This case highlights critical IP risks in modified release drug design. Choose your next step:
📋 Die Auswirkungen dieses Falls verstehen
Informieren Sie sich über die spezifischen Risiken und Auswirkungen dieses Rechtsstreits.
- View related patents in pharmaceutical formulations
- See which companies are active in modified release technologies
- Understand claim construction patterns in Brazil
🔍 Das Risiko meines Produkts überprüfen
Führen Sie eine umfassende FTO-Analyse für Ihre eigene Technologie oder Ihr eigenes Produkt durch.
- Geben Sie Ihre Produktbeschreibung oder technischen Merkmale ein.
- KI identifiziert potenziell blockierende Patente
- Erhalten Sie einen umsetzbaren Risikobewertungsbericht
Hochrisikogebiet
Secondary pharmaceutical patents (formulation)
Brazilian Law
Rigorous patentability standards
Strategic Challenges
Effective for market access
✅ Wichtigste Erkenntnisse
Brazilian invalidity actions under Article 56, Law 9.279/1996 are powerful offensive tools against pharmaceutical formulation patents.
Verwandte Rechtsprechung suchen →Article 1.025 CPC pre-questioning is essential appellate practice for preserving higher court review rights in Brazil.
Rechtliche Präzedenzfälle erkunden →Dual composition-and-process patent claims do not guarantee doubled protection — both can fall in a single invalidity action.
Umfang der Forderung analysieren →Appellate courts in São Paulo are applying substantive patentability scrutiny to formulation innovations.
Monitor court trends →Häufig gestellte Fragen
The case concerned Brazilian patent BRPI0919466B1, covering a modified release oral pharmaceutical composition and its manufacturing process.
The patent was invalidated through an invalidity and cancellation action filed by Apsen Farmacêutica. The specific technical grounds were not disclosed in available case records.
The outcome reinforces that formulation patents — including modified release compositions — are subject to rigorous validity challenges in Brazilian courts, signaling risk for originator companies relying on secondary patents for market exclusivity.
Sind Sie bereit, Ihre Patentstrategie zu stärken?
Schließen Sie sich den über 18.000 Fachleuten aus dem Bereich des geistigen Eigentums an, die PatSnap Eureka nutzen, um mit KI-gestützter Präzision Recherchen zum Stand der Technik durchzuführen, Patentanmeldungen zu erstellen und Wettbewerbslandschaften zu analysieren.
Referenzen
- Court of Justice of São Paulo (TJSP) — Case No. 2332814-55.2023.8.26.0000/50001
- INPI Brazilian Patent Database
- Brazil’s Industrial Property Law No. 9.279/1996 (Article 56)
- PatSnap – Lösungen für den Umgang mit geistigem Eigentum für Anwaltskanzleien
Dieser Artikel dient ausschließlich zu Informationszwecken und stellt keine Rechtsberatung dar. Alle Angaben zu den Fällen stammen aus öffentlich zugänglichen Gerichtsakten. Informationen zu den Funktionen der Plattform finden Sie auf PatSnap.